A Study of PRT2527 in Participants With Advanced Solid Tumors

Summary

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

Timeline

Start

2022-02-14

Primary completion

2023-12-06

Completion

2023-12-06

Drugs

Indications